Even if evidence is based on few experiences, it indicates that PLWH with malignancies should continue HAART during chemotherapy, in order to face the hematologic toxicity, that is the decrease in the number of CD4 lymphocytes and the related complications such as increasing the risk of opportunistic infections. The gene discussed is CD4; the disease is cancer.